Literature DB >> 7975848

Towards a new generation of flavivirus vaccines.

K Venugopal1, E A Gould.   

Abstract

Flavivirus diseases have caused great public health concern for over three centuries, with diseases like yellow fever, dengue, Japanese encephalitis and tick-borne encephalitis causing thousands of deaths. Although yellow fever epidemics can be brought under control by the use of vaccine or mosquito-control measures, there have been many examples of its re-emergence as an epidemic disease. Similarly, the use of vaccines or arthropod-control measures have failed to prevent the spread of other flaviviruses such as Japanese encephalitis virus. There has been rapid growth in the knowledge of molecular information on flaviviruses in the last decade, and on the basis of this information several potential recombinant subunit vaccines are being developed and appear to be effective experimentally. Moreover, the assumption that humoral immunity induced by virus structural envelope glycoproteins is the only effective means of providing protection against flavivirus infection can be questioned. This review attempts to summarize recent thinking in this field and to evaluate the different systems available as potential future flavivirus vaccines in inducing protective immunity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975848     DOI: 10.1016/0264-410x(94)90329-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein.

Authors:  S Bhardwaj; M Holbrook; R E Shope; A D Barrett; S J Watowich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

3.  Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form.

Authors:  S L Allison; K Stadler; C W Mandl; C Kunz; F X Heinz
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

4.  Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines.

Authors:  H W Chen; C H Pan; M Y Liau; R Jou; C J Tsai; H J Wu; Y L Lin; M H Tao
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression.

Authors:  G W Holzer; G Remp; G Antoine; M Pfleiderer; O M Enzersberger; W Emsenhuber; T Hämmerle; F Gruber; C Urban; F G Falkner; F Dorner
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice.

Authors:  Y L Lin; L K Chen; C L Liao; C T Yeh; S H Ma; J L Chen; Y L Huang; S S Chen; H Y Chiang
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus.

Authors:  R J Phillpotts; K Venugopal; T Brooks
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

8.  Glycoprotein E2 of bovine viral diarrhea virus expressed in insect cells provides calves limited protection from systemic infection and disease.

Authors:  S R Bolin; J F Ridpath
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Development and application of a reverse genetics system for Japanese encephalitis virus.

Authors:  Sang-Im Yun; Seok-Yong Kim; Charles M Rice; Young-Min Lee
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  The prM-independent packaging of pseudotyped Japanese encephalitis virus.

Authors:  Hee Jung Lee; Kyung-Il Min; Jungeun Lee; Sin-Hyung Kang; Wonkyung Jeon; Jae Hwan Nam; Young Ran Ju; Young Bong Kim
Journal:  Virol J       Date:  2009-07-30       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.